title: Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas.
abstract: Meningiomas arise from the arachnoidal cells surrounding the brain and are one of the most common tumors of the central nervous system. These tumors are known to be hormonally modulated and may occur in association with breast carcinoma. Overexpression of the erbB-2 oncogene product and mutation of the tumor suppressor p53 gene are considered causal driving forces in the pathogenesis of adenocarcinomas of the breast. To determine whether abnormal expression of these genes also plays a role in the pathogenesis of meningiomas, we analyzed the expression of the erbB-2 and p53 proteins in 17 atypical and 35 typical meningioma tissue specimens by immunohistochemistry. The staining intensity was assigned a relative value of 0 to 5+, where 5+ denoted confluent immunoreactivity, 4+ to 1+ denoted varying degrees of focal positivity, and 0 denoted no evidence of staining. Levels of p53 and erbB-2 immunohistochemical staining were then correlated with tumor histology. For p53 immunoreactivity, typical meningiomas had a median staining score of 1.0, compared to 4.0 for atypical meningiomas (P < 0.0001, Mann-Whitney U test). For erbB-2 immunoreactivity, typical meningiomas had a median staining score of 5.0 compared to 1.0 for atypical meningiomas (P < 0.0001, Mann-Whitney U test). The inverse relationship between levels of erbB-2 and p53 immunoreactivity was found to be statistically significant (P < 0.0001, ANOVA). Expression of the erbB-2 protein was not associated with gene amplification or the presence of activating mutation in the transmembrane region of the protein. These findings may improve our understanding of the molecular events that occur in the neoplastic transformation of meningothelial cells. The patterns of erB-2 and p53 immunoreactivity may prove to be useful markers with which to identify potentially more malignant meningiomas.
authors.affiliation: Department of Clinical Neurosciences, Brown University, Providence, Rhode Island, USA.
authors.forename: B S
authors.initials: BS
authors.lastname: Chozick
authors.forename: D L
authors.initials: DL
authors.lastname: Benzil
authors.forename: E G
authors.initials: EG
authors.lastname: Stopa
authors.forename: J C
authors.initials: JC
authors.lastname: Pezzullo
authors.forename: N W
authors.initials: NW
authors.lastname: Knuckey
authors.forename: M H
authors.initials: MH
authors.lastname: Epstein
authors.forename: S D
authors.initials: SD
authors.lastname: Finkelstein
authors.forename: P W
authors.initials: PW
authors.lastname: Finch
mesh_terms: D001483:Base Sequence; D001943:Breast Neoplasms / Q000737:chemistry; D005069:Evaluation Studies as Topic; D018734:Genes, erbB-2; D006801:Humans; D007150:Immunohistochemistry; D008577:Meningeal Neoplasms / Q000737:chemistry* / Q000473:pathology; D008579:Meningioma / Q000737:chemistry* / Q000473:pathology; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000032:analysis*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
chemical_list: D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D016159:Tumor Suppressor Protein p53